Share on StockTwits

Foundation Medicine (NYSE:FMI) SVP Jason Ryan sold 3,541 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $26.36, for a total transaction of $93,340.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on FMI. Analysts at William Blair initiated coverage on shares of Foundation Medicine in a research note on Thursday. They set a “market perform” rating on the stock. Separately, analysts at JMP Securities raised their price target on shares of Foundation Medicine from $33.00 to $45.00 in a research note on Monday, March 10th. They now have an “outperform” rating on the stock. Finally, analysts at Wedbush initiated coverage on shares of Foundation Medicine in a research note on Tuesday, March 4th. They set an “outperform” rating and a $50.00 price target on the stock. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $42.25.

Shares of Foundation Medicine (NYSE:FMI) traded down 2.35% during mid-day trading on Friday, hitting $26.54. 307,786 shares of the company’s stock traded hands. Foundation Medicine has a 1-year low of $20.00 and a 1-year high of $45.00. The stock’s 50-day moving average is $34.09 and its 200-day moving average is $30.08. The company’s market cap is $734.2 million.

Foundation Medicine (NYSE:FMI) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.48) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.43) by $0.05. The company had revenue of $9.66 million for the quarter, compared to the consensus estimate of $9.01 million. On average, analysts predict that Foundation Medicine will post $-1.81 earnings per share for the current fiscal year.

Foundation Medicine, Inc is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.